Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma

On August 1, 2019

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219

Related Post

More than 1,800 customers in Texas assisted through Entergy’s The Power to Care program

Modification to Methodology of the S&P/CLX INTER

HII CEO Tours Company Operations in Hawaii and Meets with Military and Civilian Leaders